Unveiling the hidden therapeutic potential of carnosine, a molecule with a multimodal mechanism of action: a position paper
ReviewOther animalsHumans
- Design
- Review
- Subjects
- not stated in abstract
- Dose used in the study
- not stated in abstract
- Duration
- not stated in abstract
- What was measured
- Position paper reviewing preclinical in-vivo studies of carnosine and the variation in route, dose, duration and animal model between them.
What the authors reported
The author describes carnosine as an endogenous dipeptide that is also sold as an over-the-counter food supplement, and lists its proposed mechanisms: neutralising reactive oxygen and nitrogen species, reducing pro-inflammatory mediators, inhibiting formation of abnormal proteins, and modulating macrophages and microglia. The paper states that in-vivo preclinical studies differ widely in administration route, dose, treatment duration and animal model. The author argues that coordinated preclinical studies are urgently needed before well-defined clinical trials can be designed.
Limits of this study
Single-author position paper; it argues the existing preclinical evidence base is not aligned enough to support clinical trial design.
Source
PubMed 35630780 · doi:10.3390/molecules27103303
Entry checked against full text (journal site, MDPI) on 2026-10-11. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.